Document is current
Any future updates will be listed below
-
Authors
Mijalkov, Mite https://orcid.org/0000-0002-9844-4413
Storm, Ludvig
Zufiria-Gerbolés, Blanca https://orcid.org/0000-0001-7756-630X
Veréb, Dániel https://orcid.org/0000-0003-2077-5252
Xu, Zhilei https://orcid.org/0000-0002-5155-6346
Canal-Garcia, Anna https://orcid.org/0000-0001-7460-741X
Sun, Jiawei
Chang, Yu-Wei
Zhao, Hang
Gómez-Ruiz, Emiliano
Passaretti, Massimiliano
Garcia-Ptacek, Sara
Kivipelto, Miia
Svenningsson, Per https://orcid.org/0000-0001-6727-3802
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Jacobs, Heidi https://orcid.org/0000-0001-7620-3822
Lüdge, Kathy https://orcid.org/0000-0002-4831-8910
Brunner, Daniel https://orcid.org/0000-0002-4003-3056
Mehlig, Bernhard https://orcid.org/0000-0002-3672-6538
Volpe, Giovanni https://orcid.org/0000-0001-5057-1846
Pereira, Joana B. https://orcid.org/0000-0002-4604-2711
- License Information
-
More Information
Article History
Received: 15 January 2024
Accepted: 6 March 2025
First Online: 20 March 2025
Competing interests
: H.Z. (Henrik Zetterberg) has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other co-authors declare no competing interests.
